Новые методы получения и биологически активные свойства Пиоцианина

Пиоцианин обладает противомикробной, противогрибковой и противоопухолевой активностью. Для изучения этих свойств и поиска дальнейшего применения пиоцианина, был увеличен выход пиоцианина с помощью оптимизации условий культивирования и оптимизации питательной среды.Pyocyanin has antimicrobial, antifungal and antitumor activity. To study these properties and search for further use of pyocyanin, the yield of pyocyanin was increased by optimizing cultivation conditions and optimizing the nutrient medium

Разработка технологии и проектирование участка сборки-сварки траверсы задней механизированной крепи МКЮ4У.56

Актуальность работы: в данной выпускной квалификационной работе производится проектирование участка сборки-сварки траверсы задней крепи механизированной МКЮ 4У.56. Объектом исследования является процесс изготовления траверсы. В результате данной работы следует получить производство с наибольшей степенью механизации и автоматизации повышающей производительность труда.Relevance of the work: in the final qualifying work is done tooling design and site assembly welding traverses back lining mechanized MKY 4U.56 As a result of this work should be obtained from producing the greatest degree of mechanization and automation increases productivity

24. Validation of conformal radiotherapy treatment planning systems using an antro-pomorphic phantom and thermoluminescence dosimetry

Within the requirements of a Quality Assurance programme in a radiotherapy department, the ability of a treatment planning system (TPS) to accurately calculate dose distributions under realistic conditions encountered in radiotherapy (RT) should be validated. This may be accomplished by thermoluminescence (TL) dosimetry in simulated treatment of antropomorphic phantoms. In our radiotherapy department, several planning systems are used concurrently in 3D conformal treatment of larger volumes (with irregular fields obtained via individual shielding or multileaf collimation) and of very small volumes (stereotactic technique), by external megavoltage photon beams. Realistic 3D treatment plans were prepared using CadPlan, Theraplan and BrainLab TPS for treating volumes in an Alderson phantom, which was prepared for topometry (CT-scanned) and irradiated in fully simulated conditions of patient RT. Suitably selected TL detectors (some custom-produced for these measurements), were placed inside and around the treated volumes in the phantom. For every photon beam applied (Co-60, 6 MV or 9 MV) the TL detectors, individually corrected, were calibrated in a standard solid phantom against ionisation chamber dosimetry. For irradiation of larger volumes, standard MTS-N (LiF:Mg,Ti) detectors were used. For stereotactic irradiation of small volumes in the head (6 MV) special miniature thermoluminescent LiF:Mg,Ti and LiF:Mg,Cu,P were developed. The technique of detector calibration, preparation of Alderson phantom for simulated RT, detector readout and interpretation of the measured versus calculated values of dose at measurement points inside the phantom, will be described

System-size and centrality dependence of charged kaon and pion production in nucleus-nucleus collisions at 40A GeV and158A GeV beam energy

Measurements of charged pion and kaon production are presented in centrality selected Pb+Pb collisions at 40A GeV and 158A GeV beam energy as well as in semi-central C+C and Si+Si interactions at 40A GeV. Transverse mass spectra, rapidity spectra and total yields are determined as a function of centrality. The system-size and centrality dependence of relative strangeness production in nucleus-nucleus collisions at 40A GeV and 158A GeV beam energy are derived from the data presented here and published data for C+C and Si+Si collisions at 158A GeV beam energy. At both energies a steep increase with centrality is observed for small systems followed by a weak rise or even saturation for higher centralities. This behavior is compared to calculations using transport models (UrQMD and HSD), a percolation model and the core-corona approach.Comment: 32 pages, 14 figures, 4 tables, typo table II correcte

Antideuteron and deuteron production in mid-central Pb+Pb collisions at 158AA GeV

Production of deuterons and antideuterons was studied by the NA49 experiment in the 23.5% most central Pb+Pb collisions at the top SPS energy of $\sqrt{s_{NN}}$=17.3 GeV. Invariant yields for $\bar{d}$ and $d$ were measured as a function of centrality in the center-of-mass rapidity range $-1.2<y<-0.6$. Results for $\bar{d}(d)$ together with previously published $\bar{p}(p)$ measurements are discussed in the context of the coalescence model. The coalescence parameters $B_2$ were deduced as a function of transverse momentum $p_t$ and collision centrality.Comment: 9 figure

Proton -- Lambda Correlations in Central Pb+Pb Collisions at sqrt(s_{NN}) = 17.3 GeV

The momentum correlation between protons and lambda particles emitted from central Pb+Pb collisions at sqrt(s_{NN}) = 17.3 GeV was studied by the NA49 experiment at the CERN SPS. A clear enhancement is observed for small relative momenta (q_{inv} < 0.2 GeV). By fitting a theoretical model, which uses the strong interaction between the proton and the lambda in a given pair, to the measured data a value for the effective source size is deduced. Assuming a static Gaussian source distribution we derive an effective radius parameter of R_G = 3.02 \pm 0.20$(stat.)^{+0.44}_{-0.16}(syst.) fm.Comment: 14 pages, 9 figures, submitted to Phys. Rev.

Centrality dependence of proton and antiproton spectra in Pb+Pb collisions at 40A GeV and 158A GeV measured at the CERN SPS

The yields of (anti-)protons were measured by the NA49 Collaboration in centrality selected Pb+Pb collisions at 40A GeV and 158A GeV. Particle identification was obtained in the laboratory momentum range from 5 to 63 GeV/c by the measurement of the energy loss dE/dx in the TPC detector gas. The corresponding rapidity coverage extends 1.6 units from mid-rapidity into the forward hemisphere. Transverse mass spectra, the rapidity dependences of the average transverse mass, and rapidity density distributions were studied as a function of collision centrality. The values of the average transverse mass as well as the midrapidity yields of protons when normalized to the number of wounded nucleons show only modest centrality dependences. In contrast, the shape of the rapidity distribution changes significantly with collision centrality, especially at 40A GeV. The experimental results are compared to calculations of the HSD and UrQMD transport models.Comment: 25 pages, 12 figures, submitted to PR

Energy dependence of kaon-to-proton ratio fluctuations in central Pb+Pb collisions from sNN\sqrt{s_{NN}} = 6.3 to 17.3 GeV

Kaons and protons carry large parts of two conserved quantities, strangeness and baryon number. It is argued that their correlation and thus also fluctuations are sensitive to conditions prevailing at the anticipated parton-hadron phase boundary. Fluctuations of the $(\mathrm{K}^+ + \mathrm{K}^-)/(\mathrm{p}+\bar{\mathrm{p}})$ and $\mathrm{K}^+/\mathrm{p}$ ratios have been measured for the first time by NA49 in central Pb+Pb collisions at 5 SPS energies between $\sqrt{s_{NN}}$= 6.3 GeV and 17.3 GeV. Both ratios exhibit a change of sign in $\sigma_{\mathrm{dyn}}$, a measure of non-statistical fluctuations, around $\sqrt{s_{NN}}$ = 8 GeV. Below this energy, $\sigma_{\mathrm{dyn}}$ is positive, indicating higher fluctuation compared to a mixed event background sample, while for higher energies, $\sigma_{\mathrm{dyn}}$ is negative, indicating correlated emission of kaons and protons. The results are compared to UrQMD calculations which which give a good description at the higher SPS energies, but fail to reproduce the transition to positive values.Comment: 5 pages, 4 figure

Day-to-day variations during clinical drug monitoring of morphine, morphine-3-glucuronide and morphine-6-glucuronide serum concentrations in cancer patients. A prospective observational study

BACKGROUND: The feasibility of drug monitoring of serum concentrations of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic morphine therapy is not established. One important factor relevant to drug monitoring is to what extent morphine, M6G and M3G serum concentrations fluctuate during stable morphine treatment. METHODS: We included twenty-nine patients admitted to a palliative care unit receiving oral morphine (n = 19) or continuous subcutaneous (sc) morphine infusions (n = 10). Serum concentrations of morphine, M6G and M3G were obtained at the same time on four consecutive days. If readmitted, the patients were followed for another trial period. Day-to-day variations in serum concentrations and ratios were determined by estimating the percent coefficient of variation (CV = (mean/SD) ×100). RESULTS: The patients' median morphine doses were 90 (range; 20–1460) mg/24 h and 135 (range; 30–440) mg/24 h during oral and sc administration, respectively. Intraindividual fluctuations of serum concentrations estimated by median coefficients of day-to-day variation were in the oral group for morphine 46%, for M6G 25% and for M3G 18%. The median coefficients of variation were lower in patients receiving continuous sc morphine infusions (morphine 10%, M6G 13%, M3G 9%). CONCLUSION: These findings indicate that serum concentrations of morphine and morphine metabolites fluctuate. The fluctuations found in our study are not explained by changes in morphine doses, administration of other drugs or by time for collection of blood samples. As expected the day-to-day variation was lower in patients receiving continuous sc morphine infusions compared with patients receiving oral morphine